|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:bannedIn
|
gptkb:Australia
gptkb:Austria
gptkb:Belgium
gptkb:Bulgaria
gptkb:Canada
gptkb:China
gptkb:Croatia
gptkb:Cyprus
gptkb:Czech_Republic
gptkb:Denmark
gptkb:Estonia
gptkb:Finland
gptkb:France
gptkb:Germany
gptkb:Greece
gptkb:Hungary
gptkb:Iceland
gptkb:Ireland
gptkb:Italy
gptkb:Latvia
gptkb:Liechtenstein
gptkb:Lithuania
gptkb:Luxembourg
gptkb:Malta
gptkb:Monaco
gptkb:Netherlands
gptkb:Norway
gptkb:Poland
gptkb:Portugal
gptkb:Romania
gptkb:San_Marino
gptkb:Slovakia
gptkb:Slovenia
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:Turkey
gptkb:United_Kingdom
gptkb:United_States
gptkb:Vatican_City
|
|
gptkbp:CASNumber
|
82657-23-6
|
|
gptkbp:chemicalFormula
|
C16H22Cl2N2O
|
|
gptkbp:developedBy
|
gptkb:Upjohn
1970s
|
|
gptkbp:first_identified_in_illicit_markets
|
2014
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
U-47700
|
|
gptkbp:IUPACName
|
3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide
|
|
gptkbp:legalStatus
|
Schedule I controlled substance
|
|
gptkbp:molecularWeight
|
329.27 g/mol
|
|
gptkbp:potency_compared_to_morphine
|
7.5 times more potent
|
|
gptkbp:PubChem_CID
|
50929609
|
|
gptkbp:relatedTo
|
gptkb:U-50488
fentanyl
AH-7921
|
|
gptkbp:riskFactor
|
addiction
death
overdose
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
rectal
nasal
|
|
gptkbp:sideEffect
|
nausea
constipation
itching
respiratory depression
sedation
euphoria
|
|
gptkbp:UNII
|
6E8C6M67V3
|
|
gptkbp:bfsParent
|
gptkb:BGP-2
gptkb:MPO-12
gptkb:UC-50
gptkb:U-50488
|
|
gptkbp:bfsLayer
|
8
|